Company Overview - Madi Technology closed at 15.44 yuan, up 2.93%, with a latest price-to-book ratio of 5.75 and a total market capitalization of 4.729 billion yuan [1] - As of the first quarter of 2025, there is one institutional holder of Madi Technology, holding a total of 49.2201 million shares valued at 0.637 billion yuan [1] Business Operations - Suzhou Madi Technology Co., Ltd. specializes in providing Clinical Information System (CIS) application software and overall solutions for clinical information management [1] - The company's main products include self-developed software, comprehensive solutions, purchased software and hardware, operational and technical services, medical service income, and photovoltaic battery cells [1] Financial Performance - For the first quarter of 2025, Madi Technology reported operating revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1] - The net profit for the same period was 23.5959 million yuan, showing a year-on-year increase of 138.55% [1] - The sales gross margin stood at 66.10% [1] Industry Comparison - Madi Technology's price-to-earnings (P/E) ratio (TTM) is -17.79, while the industry average is 113.36 [2] - The industry median P/E ratio is 20.17, indicating that Madi Technology's valuation is significantly lower than the industry average [2] - The total market capitalization of Madi Technology is 4.729 billion yuan, compared to the industry average of 11.359 billion yuan [2]

Group 1 - The report highlights investment hotspots in May, focusing on robotics, particularly unmanned logistics vehicles, controllable nuclear fusion, digital currencies (stablecoins & RWA), mergers and acquisitions, and military industry, with a market preference for small-cap companies [6][22][23] - The robotics sector, especially unmanned logistics vehicles, showed strong performance, transitioning from 0 to 1 stage with companies like Jiushi and New Stone achieving significant order volumes and commercial deployment [6][24][25] - The report indicates that the AI sector continues to evolve, with major advancements in AI models and applications, including the DeepSeek-R1 model's upgrade, which significantly improved reasoning capabilities and performance metrics [47][49][50] Group 2 - The report notes that the controllable nuclear fusion sector is gaining momentum, supported by U.S. policy changes and accelerated project developments in China, with significant milestones achieved in the CRAFT project [39][40] - The digital currency sector is experiencing regulatory advancements, with the U.S. Senate passing the GENIUS Act and Hong Kong establishing a regulatory framework for stablecoins, indicating a growing acceptance and potential for market expansion [42][43] - The mergers and acquisitions landscape is evolving with new regulations aimed at simplifying processes and enhancing market-driven approaches, exemplified by the merger plans between Haiguang Information and Zhongke Shuguang [44][45]

截至2025年5月30日收盘，麦迪科技（603990）报收于14.96元，较上周的14.88元上涨0.54%。本周，麦 迪科技5月26日盘中最高价报15.85元。5月28日盘中最低价报14.67元。麦迪科技当前最新总市值45.82亿 元，在软件开发板块市值排名82/133，在两市A股市值排名3107/5146。 本周关注点 成熟解决方案上率先进行产品布局，并借助公司在医疗IT领域的技术基础，通过本体、场景、大模型的 协同构建整体解决方案平台。随着每一阶段机器人能力的迭代与场景的丰富，我们将持续推出契合市场 的新功能、新形态，推动康养机器人从"单点功能"走向"体系平台"。 问：光伏业务剥离后，公司2025年度净利润能否实现扭亏？传统医疗信息化业务有哪些新的增长点？ 答：公司2024年净利润亏损主要受光伏业务产业链价格下行影响，公司医疗信息化及医疗服务业务营收 稳定。公司已于2025年1月完成光伏业务的剥离，剥离后主营聚焦于医疗信息化和大健康领域，2025年 净利润将实现同比扭亏，财务结构更加清晰。公司医疗信息化传统业务保持稳健收入来源，同时在政策 推动下，未来，随着二级医院信息化建设、临床信息系统升级、区域协同 ...

Core Viewpoint - The company, Madi Technology, is focusing on the development of AI models tailored for medical scenarios, aiming to address specific issues in real clinical settings [2][4]. Group 1: AI and Medical Applications - Madi Technology's AI strategy will concentrate on high-frequency critical conditions and decision support, integrating models deeply with business systems [2]. - The company has a competitive advantage due to its extensive deployment of medical information systems and a large accumulation of structured data, enabling practical and continuously evolving medical AI models [2]. - The company is advancing a low-altitude drone AED solution, which is faster, denser, and more cost-effective than traditional deployment methods, significantly improving the accessibility and success rates of emergency responses [2]. Group 2: Robotics and Healthcare - The company's approach to rehabilitation robots starts with non-contact services, gradually expanding to semi-contact and more complex human-machine interactions [3]. - Madi Technology has extensive experience with hospital clients, providing a solid foundation for developing customized hardware and software solutions for various healthcare settings [3]. - The company has shifted its revenue structure to focus on high-value, high-margin medical services after divesting its solar business, enhancing its risk resilience and sustainable growth potential [3]. Group 3: Business Developments - Madi Technology's subsidiary, Haikou Mary Hospital, is the second private hospital in Hainan to obtain a reproductive medicine license, completing 1,306 egg retrieval cycles in 2024 with a revenue of 61.6 million yuan [3]. - The company plans to leverage the Hainan Free Trade Port policy to expand its core technologies and management practices into Southeast Asia and international markets [3]. Group 4: Corporate Governance - The company held its 2024 annual shareholders' meeting on May 20, 2025, where multiple resolutions were passed, including financial reports and plans for external financing [5].

北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 法律意见书 二〇二五年五月 法律意见书 北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 法律意见书 致：苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"） 北京市中伦（上海）律师事务所（以下简称"本所"）接受公司的委托，指 派律师出席并见证公司2024年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《苏州麦迪斯顿医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 资格、会议表决程序及表决 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-036 苏州麦迪斯顿医疗科技股份有限公司 2024年年度股东大会决议公告 | 1、出席会议的股东和代理人人数 | 263 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 71,761,487 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 23.7087 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 本次股东大会由副董事长翁康先生主持，会议采用现场投票与网络投票相结合的 表决方式进行表决。本次会议的召集、召开符合《公司法》《公司章程》《公司股 东大会议事规则》等法律、法规和规范性文件的规定。 (五)公司董事和董事会秘书的出席情况 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 20 日 (二)股东大会召开的地点：江苏省苏州市工业园区归家巷 222 号麦迪科技会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 二、 议案审议情况 本公司董事会及全体 ...

北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 法律意见书 二〇二五年五月 北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 致：苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"） 北京市中伦（上海）律师事务所（以下简称"本所"）接受公司的委托，指 派律师出席并见证公司2024年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《苏州麦迪斯顿医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书 ...

Core Viewpoint - In 2024, Madi Technology faced significant revenue decline primarily due to challenges in the photovoltaic business, leading to a total revenue of 464 million yuan, a year-on-year decrease of 24.93%, and a net profit attributable to shareholders of -279 million yuan [1] Financial Performance - The photovoltaic segment's revenue dropped sharply by 44.04%, contributing to a gross margin decline [1] - The software and information technology services segment generated 232 million yuan in revenue, down 10.92%, with a gross margin of 72.50% [1] - The medical services segment achieved 61.6 million yuan in revenue, an increase of 8.83%, with a gross margin of 39.57% [1] - The photovoltaic business reported a revenue of 168 million yuan, with a gross margin of -77.83% [1] Technological Innovation - Madi Technology made significant advancements in technology, launching a comprehensive smart operating room solution integrating IoT, big data, AI, and digital twin technology [2] - The company established a low-altitude economy innovation center and developed an autonomous AED drone rescue solution [2] - Collaborations with various tech firms aim to enhance medical service robots and create a 5G+ IoT critical care solution [2] Industry Outlook - The medical informationization sector is projected to grow rapidly, with the market expected to exceed 140 billion yuan by 2030 [2] Future Strategy - After divesting the photovoltaic business, Madi Technology reported a net profit of 23.6 million yuan in Q1 2025, a year-on-year increase of 138.55% [3] - The company plans to focus on medical informationization, enhancing platform, regional, and intelligent upgrades, and integrating AI technology into products [3][4] - Madi Technology aims to develop a product system combining software platforms, smart hardware, and algorithm engines, targeting areas like smart surgery and elderly care [4]

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

苏州麦迪斯顿医疗科技股份有限公司 2024 年年度股东大会会议资料 苏州麦迪斯顿医疗科技股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月二十日 1 苏州麦迪斯顿医疗科技股份有限公司 2024 年年度股东大会会议资料 苏州麦迪斯顿医疗科技股份有限公司 2024 年年度股东大会会议资料目录 | 2024 年年度股东大会会议须知 3 | | --- | | 2024 年年度股东大会议程 5 | | 议案一：关于公司 2024 年度董事会工作报告的议案 7 | | 议案二：关于公司 2024 年度监事会工作报告的议案 8 | | 议案三：关于公司 2024 年度财务决算报告及 2025 年度财务预算方案的议案 9 | | 议案四：关于公司 2024 年年度报告及报告摘要的议案 17 | | 议案五：关于公司 2024 年度不进行利润分配的议案 18 | | 议案六：关于 2025 年度公司及控股子公司对外申请融资额度的议案 19 | | 议案七：关于预计 2025 年度为子公司提供担保额度的议案 20 | | 议案八：关于确认公司 2024 年度非独立董事薪酬及 2025 年非独立董事薪酬方案的议 | ...